Stats

Premises: own ledger empty, so these are prospective exposures, not holdings. Issuer primary disclosures retrievedSep21: EEM Sep17 technology42.24%,Taiwan28.10%,Korea20.60%,China19.94%,PE19.40/PB2.69; IWM Sep17 PE18.31/PB2.11 and1957holdings,Aug31 beta1.24/volatility19.61%; QQQ tracks100largest Nasdaq nonfinancials, current weight widgets failed. Sources https://www.ishares.com/us/products/239637/ishares-msci-emerging-markets-etf ; https://www.ishares.com/us/products/239710/ishares-russell-2000-etf ; https://www.invesco.com/qqq-etf/en/about.html . Bear EEM: technology/Asian concentration permits common earnings and FX shock despite geographic label. Bear QQQ: large nonfinancial growth expectations can disappoint together, leaving long-lookback momentum late to reversal. Bear IWM: weaker financing/demand could pressure smaller businesses while only3.727% decline reaches SMA. These are conditional mechanisms, not measured new Sunday events or constituent balance-sheet claims. Counterarguments: exports/earnings may strengthen, QQQ cash generation may sustain prices, domestic recovery may support IWM. Issuer ratios alone prove neither overvaluation nor an entry veto. Brokers/issuers earn on participation; investor return still depends on price and cashflows. What changed today: completed crypto Sep20 and rolling target window; no new equity close. Weekend geopolitical headlines in context not independently corroborated here, therefore no causal trade conclusion. Fixed price rule remains long; no stop/target to reset on an empty book.

Premises:1 XLE issuer Sep17 has21holdings, forwardPE12.46 versus historical17.82, concentrated energy operations https://www.ssga.com/us/en/individual/etfs/state-street-energy-select-sector-spdr-etf-xle ;2 EEM issuer Sep17 IT42.24%, Taiwan/Korea/China68.64% combined,PE19.40 https://www.ishares.com/us/products/239637/ishares-msci-emerging-markets-etf . XLE strongest bear: high commodity cash expectations reverse through demand destruction or restored supply; forward earnings may fall while multiples contract. Illustrative assumption earnings-20% and multiple-10% implies equity-28%, $18.0068 per share before stop, not forecast. Counterexample durable supply scarcity may sustain earnings, downstream businesses differ. EEM strongest bear: technology slowdown/trade friction and dollar appreciation hurt earnings and USD translation simultaneously;1185names do not eliminate correlated exposure. Counterexample demand recovery/currency appreciation. Who benefits: energy producers from pricing, exporters from demand; managers from assets. No verified new operating event today: provided Saudi/summit headlines are uncorroborated hypotheses, not independent evidence. Fixed signals persist, so bear cases inform gap limits rather than discretionary exit. Sources close to portfolio composition, not proof of future returns. Dividend calendarSep21/paySep23 confirmed, workbook still June; actual XLE fill trade-date absent, entitlement unknown. No dividend cash credited to payoff.

Premises:1 Own ledger has no holding, so review concerns prospective XLK/XLE/XLV, not trend-ws XLE.2 Issuer Sep17 snapshots accessedSep21: XLK FY1PE26.17/Pcashflow28.60/estimatedgrowth36.25%; XLE12.46/8.77/10.87%; XLV20.04/17.71/11.77%. Sources https://www.ssga.com/us/en/intermediary/etfs/state-street-technology-select-sector-spdr-etf-xlk ; https://www.ssga.com/us/en/intermediary/etfs/state-street-energy-select-sector-spdr-etf-xle ; https://www.ssga.com/us/en/intermediary/etfs/state-street-health-care-select-sector-spdr-etf-xlv .3 Forward earnings are estimates, multiples not causal timing signals. Strongest XLK bear: high embedded growth can disappoint and compress valuation; counterexample sustained cash growth can support premium. XLE bear: cheap forward multiple can be a peak-earnings trap if realized energy prices fall or costs rise; counterexample sustained profitable scarcity. XLV bear: lower expected growth plus20xforward may not cushion reimbursement/cost/earnings disappointment; counterexample resilient paid demand. Beneficiaries of optimism include existing shareholders; fund issuer earns fees regardless of our timing. No new company cash-flow evidence verified tonight, so none of these conditional hypotheses is a claimed new event. Conclusion maintain fixed selection and evidence-based exits. Scope excludes single names/crypto/non-US substitutions. Soundness limited by estimates and snapshot timing; valid implication is risk awareness, not discretionary rotation.

Premises: Jun30 issuer release for May31 fiscal year https://www.sec.gov/Archives/edgar/data/320187/000032018726000076/q4fy26exhibit991er.htm . Q4 Direct sales-7%, wholesale+4%, total-1%; reported margin49.2% contains approximately900bp expected tariff recovery. Arithmetic ex-benefit about40.2%, compared reported prior40.3%, not claimed issuer non-GAAP series. EPS.72 less .52 recovery=.20 arithmetic; cannot annualize one seasonal quarter into fair value. Expected986m recovery distinct from approximately300m tariff cash received in full-year operating cash. Who benefits: tariff repayment initially benefits importer balance sheet; retail discounting may transfer some to customers. First stronger wholesale shipments may improve utilization; second sell-through determines future reorders versus inventory; third sustained cash permits reinvestment/dividends but initial shipment recovery may reverse. Counterexample to bearish put: brand recovery, cash9bn and already weak stock can absorb weak sales. Directional narrative alone does not rescue NKE3.50x P80 failure. Goal executable convex return, binding constraint payoff at actual ask; no position.

Premises from issuerJune25 Q1FY27endedMay31 SEC https://www.sec.gov/Archives/edgar/data/1070235/000107023526000071/q1fy27ex-991.htm : revenue152.9m,+26%; adjustedEBITDA36.3m; OCF4.6m, cash/investments422.9m; repurchases10m. CashconversionOCF/EBITDA12.67%,buybacks2.17xOCF; neither represents recurring freecashflow. QNXrevenue72.3m,+26%; SecureCommunicationsARR220m/DBNRR92% show retention weakness despite reportedgrowth. FY27adjustedEPSguide.16–.20 gives39.95–49.94x atSep18S7.99; accountingadjustments andgrowth make this no standalonefairvalue. Q2revenue137–148m andOCF0–10m are guide, notconsensus. Conclusion: bullcase profitableQNXscale versus bearcase weakcashconversion andlicensemix; neither fixes timing ordirection odds. Wouldupgradeonactualrecurringcash/retentionimprovement anddowngradeonburn/ARRerosion, while preserving optiongates. Factsareissuerreports; surpriseprobabilitiesunmeasured.

Premises:1 WORissuerJune23FY2026sales1.4bn+20%,acquisition121.7m/organic9%,adjustedEPS3.37,FCF170.2m+7%; Q4sales371.5m+17%,44.1macquisitions/3%organic,EPS.97vs1.06. AtS57.38trailingadjustedPE17.03,notfairvalue.2 MRKFeb3FY2025WINREVAIRsales1.4bn/company65bn=2.154%; Sep21HYPERIONlabelreview notinitialapproval; no6matchedlabel-eventstudyestablishedthisrun.3 Affordability bindsWOR beforevaluation: min67>30; MRKcheapOct2C162.5.16 needs10.751%up,matchingeventedgeunknown. Conclusion: dates qualifyresearch,notdeployment. Counterexample: smallreportedproductsharecanhavegreatergrowthvalue; declineinWORquarterlyEPSdespitesalesgrowthcanreflectmix/acquisitionexpenses. Neitherfactprovesdirection. Change mind onactualcash/orders/labelterms plusqualifiedattainablecontract. Sources https://ir.worthingtonenterprises.com/news/news-details/2026/Worthington-Enterprises-Reports-Fourth-Quarter-and-Full-Year-Fiscal-2026-Results/ ; https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/ ; MRKJune3010Qsource30855.

1.Sep4Dorian99%calendar days fixed>88000/dayexcludingdemurrage,25fleet https://www.dorianlpg.com/newsroom/news-and-press-releases/news-details/2026/Dorian-LPG-Ltd--Announces-VLGC-Newbuilding-Contracts-Forward-Chartering-Estimates-and-New-Credit-Facility/default.aspx . Illustrativeconstantfleet25*92*.99*88000=$200.376mfixedTCEproxy,notguidanceorrevenueforecastbecauseactualfleetdays/poolallocationvary;residual1%with10000/dayuplift=$.23m. Cannotapplyfreshspotrateupliftto100%ofdays. 2.BWAug28Q3fixed92%availabledays88000,2H41%TC44100+4%FFA48000 https://www.sec.gov/Archives/edgar/data/1649313/000110465926102581/bwlp-20260630xex99d1.htm . UsingQ2available3713dayssolelyasconstantQ3proxy,8%open*10000uplift=$2.9704m,notwholefleet$37.13m. 3.BWQ2OCF205.9-capex13.3=192.6m;H1371.4-24.7=346.7m beforeNCI/otherclaims;notautomaticallyownerFCF. Risingindexcharterhire7.7mabsorbedrents;ProductServicesrealized127.4/unrealized-145.5 showswhyselectivecashprofitclaimsmislead https://www.sec.gov/Archives/edgar/data/1649313/000110465926102581/bwlp-20260630xex99d2.htm . 4.Illustrative40dayvoyagenetfreightmargin3.52m at88000/day:5unpaiddaysdiluteTCEto78222.22;15to64000. Maintaining88000requiresadditional440000/1.32mnetfreight,12.5/37.5%or11000/33000peroriginalday,BEFOREextrabunkers. 40days/5daysareassumptions,15daysrouteadvantagefrom10K https://www.sec.gov/Archives/edgar/data/1596993/000159699326000025/lpg-20260331x10k.htm . 5.Strongbull:forwardquartercashalreadybookedandlaterquarterrentmaypersist;bear:unpaidtime,costs,35%orderbook andnew2030capex345m weakenpermanentpeakcapitalization. Nojustifiedequitytargetfromone-quarterTCE;netdebt,currentNAV/Q4fixturesremainneeded. Noorderfromtheseproxies. Validconditionalarithmetic,soundnesslimitedbyfleetdays,collectionandselectedrates.

Premises:1 issuer calendar https://www.ssga.com/library-content/products/fund-data/etfs/us/distribution/SPDR_Dividend_Distribution_Schedule.pdf page3 lists XLE ex/recordSep21,paySep23;2 fresh issuer workbook https://www.ssga.com/library-content/products/fund-data/etfs/us/spdr-etf-historical-distributions.xlsx has111XLErows with latestJun22 .384876, not September;3 no actual holding exists, onlypendingone-sharebuy. Conclusion Monday buyer is not entitled to that ex-date distribution; do not add hypothetical cash to target payoff or assume exact mechanicalpricegap. Distribution shifts fund assets into holder cash rather than creating operatingvalue. Fees already accrue inNAV; no double subtraction. Who benefits: entitled holders receive cash, manager earns recurring fees; no dividendcapture windfall established. Missing amount could explain Mondayprice/orderadjustment differences, but not basis for discretionarycancellation withinATR. Verify actual order and fill then reconcile exits. Bound research at issuer original; amount unverified remains explicit gap.

1. July29issuerFY2026 guideexlagEBITDA980–1020m andFCF>300m; June30netdebt1760m/shares135.527728m. https://www.sec.gov/Archives/edgar/data/1563411/000156341126000190/a2026-q2xearningspressre.htm . Sep18price25.55 from https://runway.adityaperswal.workers.dev/data/stock-bars impliesmarketcap3462.733m,EV5222.733m,5.223xmidguideEBITDA and8.664%FCFfloor yield. EVsimpledebt+marketcap omitsotherclaims;JuneinputsnotSeptemberbalance. 2. H1FCF95 andexlagEBITDA572=>16.61%cashconversion;H2FCF>205 vsH2EBITDAguide408–448 highlightsworkingcapitalneed, notpureearningsrunrate. 3. Same300FCFat7/8/10%requiredyield implies31.622/27.670/22.136. HypotheticalcurrenttrueATRnet3R31.489 requires341.406mFCFat8% or426.758mat10%. 6x1000EBITDA less1760debt gives31.285, belowhurdle;7xgives38.664. Allmultiples/yieldsareassumptions, notidentifiedmispricingorapprovedtarget. PriorFY720segmentEBITDA case at6xgives18.889;720fromissuerQ1deck https://res.cloudinary.com/constellium/image/upload/v1777451282/PDF%20documents/Earning%20Results/2026/2026_-_Q1_-_Earnings_Presentation_vF_n8bknp.pdf . 4. Strongbullcase: currentguidanceincludesknownOswegorestart; qualification/recyclingandworkingcapitalreleasecoulddeliver>300withoutpermanentscarcity. Countercase: tightermetalspreadsandcompetitorrestartreduceprofit; fullguidecashnotyetrealized. Conclusion: attractivewatch, no defensiblepointtarget selectedmerelytopass3R. Needcurrententryanddurablecashsupport; observedfacts endatissuerfigures andspot, grid ismodel.

Premises: Jul24 LW issuer results forFYendedMay31: OCF942.9m-capex410.1m=FCF532.8m. OCFgrowth74.6m includes55.1m favorableworkingcapital; higher accruals are not recurring owner earnings. FY27OCF750–800m minuscapex380–410m gives340–420mFCF,21.17–36.19% belowFY26. AtS46.67 and guide137.5–139mshares impliedequity6.417–6.487bn, forecastFCFyield5.24–6.55%; EPSguide2.95–3.25 gives14.36–15.82x. These are scenario valuations, not price targets. Q4 NAvolume+11%/EBITDA+17% counters bearishInternational EBITDA-81%; extra week andprice/mix complicate comparison. Favorable customerretention could defeat the put. SFIXJune10 Q3FCF6.5m versusbuybacks15.1m, cash/investments229.4m/no debt: improvedrevenue andclienttrend counter crash thesis. HALOSep17 $1.3bnconvertible with cappedcalls is excluded as financing-explained breakout, rather than importing its large historical tail. Sources: https://news.lambweston.com/news-releases/news-release-details/lamb-weston-announces-q4-and-full-year-fiscal-2026-results ; https://investors.stitchfix.com/news-events/press-releases/news-details/2026/Stitch-Fix-Announces-Third-Quarter-of-Fiscal-2026-Financial-Results/default.aspx ; https://www.sec.gov/Archives/edgar/data/1159036/000115903626000126/ex-991xhaloxpricingpressre.htm . Issuers are primary but favor positive framing. Valuation is not evidence of earnings surprise. LWOct6date fromSep8issuer, SFIXSep23AMC fromSep2issuer.

Premises: 1. CSTM2025model targets metal-price neutrality through pass-through/hedges, not windfall from cheaperingots; top10suppliers49%metalvolume, top10customers56%sales. Qualification protects relationships but contracts can be repriced/terminated and inputs may not fullypass through. https://www.sec.gov/Archives/edgar/data/1563411/000156341126000057/cstm-20251231.htm . 2. July29Q2issuer attributes higher automotive sheetshipments partlyto NorthAmerican supplyshortages:68ktvs59, while totalshipments381ktvs384. H1segmentEBITDA572 excludes226noncash metallag; issuerFCF95 after149capex/10PPEinflows; workingcapitaluses457. AnnualFCF>300 requiresH2>205; guidance is notreceipt. https://www.sec.gov/Archives/edgar/data/1563411/000156341126000190/a2026-q2xearningspressre.htm . 3. CENX inputhedges partlyoffsetmetalupside:500ktpyGlencore+540ktpyConcordalumina contracts,~70%IcelandpowerLME-linked. https://www.sec.gov/Archives/edgar/data/949157/000162828026013788/cenx-20251231.htm . H1OCF236-capex134.4=101.6m, withseparateHawesville200mcashsale. Glencore45.5%H1sales, manufacturingcreditreceivable225.2m; July94.3mrefund laterthanJuneCF. https://www.sec.gov/Archives/edgar/data/949157/000162828026054308/cenx-20260630.htm . 4. Strongbullcountercase: CENXQ3EBITDA325–345mguide aftercompletedMtHolly90potrestart; CSTMguidance980–1020exlag and>300FCF. https://www.sec.gov/Archives/edgar/data/949157/000162828026054300/a20260630q2ex991earningsre.htm . Conclusion: both maybenefit despiteopposite supplychainpositions; cash,duration andstockprice—notlabels producer/buyer—decidevalue. Soundness limits: issuerperiodsJune, noSeptpaidnetback orcurrentorderbook, consolidatedCENXcashincludesnoncontrollingoperations, insurancegainsnotidenticalcash. These are fourquarterly/annualdocumentsfromtwoissuers, notfourindependentcorroborations.

Premises:1 Sep17issueroriginal rereadHTTP200:1.3bn1.5%notes,1275mnet;162.5mcappedcalls,217m2027-note cashrepurchase,435.5m2028 repurchase.2 Residual460m,incrementannualcoupon19.5-.37925-2.2=16.92075m; expectedSep22closeconditional.3 Conversion139.84/cappedcall208.39 are contractualterms,notfairvalue. Conclusion: fundingextendsmaturity but cannotprove organicdemandbehind6.93xvolume; existingsettlementmonitor434appropriate. No new company valuation ortruehedgeposition inferred. Source https://ir.halozyme.com/news/news-details/2026/Halozyme-Therapeutics-Inc--Announces-Pricing-of-Upsized-Private-Offering-of-1-3-Billion-of-Convertible-Senior-Notes-due-2033/default.aspx

Premises: (1) Customer notices Sep7/Sep15 quote ethyl105->112,anhydride102->114,butyl121->138,propyl172->150 INR/kg under immediate-payment terms: changes+6.67/+11.76/+14.05/-12.79%. https://www.laxmi.com/documents/default.aspx?f=customer-info/price-announcement-1048.pdf ; https://www.laxmi.com/documents/default.aspx?f=customer-info/price-announcement-1049.pdf . Four unweighted listquotes, notinvoiceindex. (2) July29 Q1FY27 deck: EBITDA1143mINR/11.8%, revenue9683m, newLoteethylcapacity commissioned; top10customers23%,exports35%. Juneperiod predatesAuguststockouts. https://www.laxmi.com/documents/default.aspx?f=investor-relations/q1fy27-laxmi-earning-deck-july-29-2026-563.pdf . (3) July30call Essentials11–12%margin but mid-single-digitthroughcycle expectation; demandstocking/deferral mixed. https://www.laxmi.com/documents/default.aspx?f=investor-relations/transcript-of-investor-meet-july-30-2026-568.pdf . (4) FY26 annualreport printedp130 top10tradinghouses87.6%of21.2%traderpurchases=>18.5712%allpurchases, not87.6%allvendorconcentration; payable-days138vs102. Consolidatedp252 OCF1748.97-capex6024.54=-4275.57mINR; growthcapex, notsteadymaintenancecash. https://www.laxmi.com/documents/default.aspx?f=investor-relations/annual-report-20252026-557.pdf . (5) EMN Q2intermediates spreadsbenefit chieflyolefin/derivatives; cannotattribute alltoacetyl, and its formerTexasCity600kt nowINEOS. https://www.eastman.com/en/media-center/news-stories/2026/eastman-announces-second-quarter-2026-financial-results ; https://www.ineos.com/businesses/ineos-acetyls/acetyls-in-america/who-we-are/ . Conclusion: rejectsimpleCEwinner/Laxmiloser binary. Scarcity reallocatescustomerworkingcapital and rewardsavailableproduct; ownproductionlosses mayreversemarginbenefit. AnnualFY26cash, JuneFY27margins andSeptemberallocation canallbetrue. MissingSeptemberrealizedproductmix/paidvolumes, vendoridentities, landedexportparity; foreignvenueeligibility unverified so noLXCHEMorder. CrisilNov2025creditnote isdatedbaseline,notcurrentratingprediction.

Question: can September Indian acetyl allocation invalidate August's expected Western Hemisphere normalization? Start: Supply120USD cash, no lots; goal: capture retained bottleneck rent; binding constraint: persistent paid margin at a defensible equity valuation. Premises: (1) August4 deck reports Q2Acetyl EBIT321m and Q3forecast220–250m; midpoint decline86m/26.79%. https://www.sec.gov/Archives/edgar/data/1306830/000130683026000114/q220268-kex991b.htm . Counterexample: September disruptions could extend Q2 rents; no new realized bridge found. (2) Q2issuer cash reconciliation gives H1FCF143m after14mNCI distributions, not157m simpleOCF-capex; 700–800guide needsH2557–657, only4.11–22.80% above2025H2535m. Seasonality counters a bearish annualization. https://investors.celanese.com/news/celanese-corporation-reports-second-quarter-earnings/4f485280-d86f-43f3-8068-de01ca04a02c . (3) June netdebt10643m versus market equity4983.70m at45.41; shares109.748926m. https://www.sec.gov/Archives/edgar/data/1306830/000130683026000117/ce-20260630.htm ; https://runway.adityaperswal.workers.dev/data/stock-bars . Working-capital reversal may deliver cash without extra margins; AR use399m is not proof of bad debts. (4) Forward EPS~6 implies7.57x, forecastFCF yield14.05–16.05%; attractive IF durable. Reverse net3Rprice56.287 needs recurringFCF617.74m at10% yield,741.29m at12%,926.62m at15%. Yield requirements are explicit assumptions, not observed fair multiples. Midguide750m at12% gives56.95 but15% gives45.56; choosing12% merely to clear3R would be circular. (5) Preserving an extra86mAcetyl EBIT for onequarter adds~0.72EPS atissuer8%tax or0.55–0.63 at20–30%normalized tax, not an annual perpetuity. (6) August31 Nutrinova sale152m for19%/4mprior earnings=38x,1.385/share and1.43%netdebt; conditionalQ4close. Buyer funds transitional diketene facility; nofreecash credit for reimbursed costs. https://investors.celanese.com/news/celanese-to-sell-additional-shares-of-nutrinova-joint-venture-to-mitsui-and-co-ltd/2685762a-445e-4def-b7f3-9799963cfd59 . Conclusion validity: reliable low-cost supply can monetize dislocation; regional quote inflation alone does not entail CE shareholder appreciation. Soundness: filings support prior cash and supplier topology, notSeptemberplant output/paidnetbacks or cashduration. Prior positive onintegration remainsconditional; evidence ofAcetyl retained86m quarterly increment AND comparableH2cash>=557m would materially strengthen case, normalization/ownoutage weakens it. No newprice target adopted; no cash-double-count with debtpaydown.

Premises:1 issuer EEM distributions https://www.ishares.com/us/products/239637/ishares-msci-emerging-markets-etf latestJun15 .350802 andDec16 .763266 total1.114068 per share across those two payouts;2 issuer XLE workbook https://www.ssga.com/library-content/products/fund-data/etfs/us/spdr-etf-historical-distributions.xlsx latestJun22 .384876, priorMar23 .385178; historical then-share units must be normalized forDec5split before adding older payments;3 primary calendar https://www.ssga.com/library-content/products/fund-data/etfs/us/distribution/SPDR_Dividend_Distribution_Schedule.pdf setsXLE exSep21/paySep23, amount not in downloadedhistory. Dividend payouts distribute accumulated income; not new value at exdate. Fund fees accrue inNAV, do not double subtract from adjusted returns. Investor eligible beforeexdate receives cash but price can fall; Mondaybuyer does not receive this payout by issuer exdate definition. Who benefits: entitled holders receive income, managers earn fees; no dividend-capture windfall established. No valuation override of fixed momentum; no new underlying cashflow forecast.

Premises:1 Sep17 HALO priced1.3bn1.5%notes, expectedSep22conditionalclose;1275mnet less162.5mcappedcalls and652.5mold-note cashrepurchases leaves460m,not1.3bnfreecash. Grossprincipal increases928.3m;annualcouponincrement16.92075m beforeotherdebtchanges.2 Issuer explicitly flags hedge purchases/old-note unwind aroundpricing; actualfractionofSep18volume unknown.3 THSep10secondary16.1mshares at18.50 producednocorporateproceeds;companyrepurchased1.693599msharesusingcashandABL. Conclusion: breakout eligibility persists,butvolume cannotbe countedasanindependentvoteoforganiccustomeracceleration. Strongcountercase: sustainedroyaltygrowth/contractconversion stilldrivetrend afterhedges; currentdata do notseparatecauses. Start100cash/1000equity;goalqualifiedsmalllongoption;bindingconstraint executableaffordablepremium andforecasttransportability. Noexactfutureearningsdateinvented. Sources https://ir.halozyme.com/news/news-details/2026/Halozyme-Therapeutics-Inc--Announces-Pricing-of-Upsized-Private-Offering-of-1-3-Billion-of-Convertible-Senior-Notes-due-2033/default.aspx and https://investors.targethospitality.com/news/news-details/2026/Target-Hospitality-Announces-Closing-of-Upsized-Secondary-Offering-and-Concurrent-Stock-Repurchase-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares/default.aspx . Settlementisfinancingmechanics,notdrugapproval; noautomaticpre-eventexit solelybecausepaymentsettlesSep22.

Premises:1 issuer cash distributions .763266 Dec16 2025/.350802 Jun15 2026 total1.114068/share;2 issuer hypothetical performance reinvests dividends/capital gains and deducts fund expenses;3 provider all adjusts dividend prices. Sources https://www.ishares.com/us/products/239637/ishares-msci-emerging-markets-etf and https://docs.alpaca.markets/us/reference/stockbars . These receipts explain why split-only25.8543% differs from total-return proxy28.3116%; cash payout is transferred value, not additional gain to add again to adjusted returns. Issuer benefits from fund inflows; cash dates/amounts useful independently of marketing. Counterexample: NAV total return differs from traded-market return due to fair value/premiums, and venue may not reinvest automatically. Therefore do not equate signal performance or price target with exact investor realized total return; retain mandate P90 calculation convention. Actual ledger cash credit treatment not verified this run.

Premises:1.BTDR August operating update reports86mUSD annualized last-day cloud contracted revenue,92% GPU utilization and >800m expected A1 revenue beginningQ1 2027, not current cash: https://ir.bitdeer.com/news-releases/news-release-details/bitdeer-announces-august-2026-production-and-operations-update .2.Q2 OCF-158.523m less266mcapex=-424.523m; adding195.5m digitalasset sales gives-229.023m economic funding proxy, while428.9m financing supported cash. https://www.sec.gov/Archives/edgar/data/1899123/000121390026086938/ea030131301ex99-1.htm .3.AMTX18m-liter procurement allocation is ~23.775% annualized80m-gallon capacity, not capacity shortage; H1 FCF-27.522m and debt sweeps mean creditors can capture improved receipts before shareholders. https://aemetis.com/aemetis-india-subsidiary-begins-biodiesel-deliveries-under-17-million-allocation-from-omcs/ ; https://www.sec.gov/Archives/edgar/data/738214/000143774926026052/amtx20260630_10q.htm .4.RSGN backlog357.9mCHF+17.1% coexists with order intake-10%, organic sales-9%,11.5mFCF and71.4mnetdebt. Sep16 publication confirms earlierAug5 figures, not fresh order acceleration. https://ir.the-rsgroup.com/news/rands-group-publishes-semi-annual-report-2026/d0818ab8-90b1-4cb1-83ff-5a1f617aa2ae . Conclusion: watch contracting and collections, reject current entries. Countercase: prepaid customers and funded commissioning could transform BTDR cash; AMTX successful volume/credit monetization could reduce leverage. Binding constraint is financing plus retained margin, not headline revenue. No current calibrated target or zero-loss assumption.

Premises:1 HALO June30 filing H1OCF420.969m versus253.932m and231m cash/marketables; average mid-single-digit partner-sales royalty. Aug6 issuer Q2revenue481m/royalties307.7m; adjustedEPSguide8.65–9 implies12.49–13.0x at112.45. Recurring paid royalties support operating case, but milestones/patents/partner concentration and adjusted-vs-GAAP differences constrain valuation.2 TH Aug10 Q2revenue85.5m(+39%),netloss9m,adjEBITDA18.2m;H1OCF111m dominated by customeradvances.1.4bn multi-year awards/9000beds are not annual revenue;20000bed pipeline not contracts. Sep10secondary16.1mshares at18.50 proceeds tosellingholders, not corporatecash.3 NEO Jul28 Q2revenue202m(+11%),clinical187m(+14%),netincome2m includes11m debtgain,OCF20m. Aug26coverage adds thirdRaDaRindication,two morepending with no deadline.4 HZO Aug10agreed53cash versus52.56stock; Oct16C55 cannotpay from announcedconsideration, and prior standalonebreakouttails do not price dealbreaks. Validity: paid activity can support tails but does not prove directional probability. Countercases: HALO royalty setbacks;TH advances fundfuturecosts;NEO coveragewithoutprofitablevolumes;HZO competingbid/termination. Start100cash; goal small qualifiedlongoptions; bindingconstraints currentask<=.30 and actualhistoricalcomparablepayoff. No new datedeventinvented;HALO/TH considered under technicalbreakoutmandate. Sources observations30001–4; NEO https://ir.neogenomics.com/news-events/press-releases/detail/336/neogenomics-reports-second-quarter-2026-results and /detail/337/neogenomics-receives-medicare-coverage-for-radar-st-for-immunotherapy-treatment-response-monitoring . Exactcourtcalendar not verified, not prerequisite for breakout eligibility.

Premises:1.Sep10 operator report AugustrevenueNT2785.7m,+33.3%YoY/-1.3%MoM, cites persistentAI-memory imbalance https://www.chipmos.com/english/news/news-detail.aspx?NID=234 .2.Aug11 Q2 release GM18% vs13.8%Q1, EPS.80USD/ADS andH1FCF23.1m https://chipmostechnologiesinc.gcs-web.com/news-releases/news-release-details/chipmos-reports-second-quarter-2026-results-record-high .3.Apr14 20-F: top5customers61%, top3 23/15/9%, generally3monthnonbindingforecasts; suppliers limited/no long-termcontracts and3–6monthswitching https://www.sec.gov/Archives/edgar/data/1123134/000119312526153743/imos-20251231.htm . Conclusion: growth andmarginrecovery real, but upstreaminputs/equipment and largecustomers can capture rent. Shareprice61.30 implies19.16x annualizedQ2 EPS3.20,24.52x annualizedH1 EPS2.50. These are illustrative run-rates, not forecasts; higherQ2 partlyFX/assetvaluation rebound. Atfixed2ATR risk4.30082, net3R target will exceed74: requires >23x peak-quarter annualEPS or furtherEPSgrowth. Binding constraint is defended forwardcash/valuation, not currentpriceentry (which passes). Strongcountercase: continuedmemorypricing/utilization can accelerate earnings beyondQ2; monitor without assuming today'searningsceiling. Taiwanese94TWD and USADS cannot be arbitraged with staleFX/asynchronouscloses;20shares/ADS verified, no FX-adjusted arbitrage claim. Annualfiling andmonthlyPR oneissuerorigin, Taiwan/USprice series samestockexposure.

Start: CE45.41, no position. Goal: capture incremental acetyl cash before guidance. Premises:1.Laxmi's direct Sep7/15 notices maintain allocation and immediate-payment pricing https://www.laxmi.com/documents/default.aspx?f=customer-info/price-announcement-1049.pdf ; three prices rose6.67/11.76/14.05% in8days, n-propyl fell12.79%, so uniform pricing claim fails.2.CE Aug4 Q2 disclosure reports acetyl price+22% sequential and EBIT321m, but Q3 EPS1.35–1.75 assumes moderation https://investors.celanese.com/news/celanese-corporation-reports-second-quarter-earnings/4f485280-d86f-43f3-8068-de01ca04a02c . Different dates and regions can make both true: Indian landed shortages need not raise CE Western Hemisphere realized netbacks.3.June30 debt12007-cash1364=10643m; H1FCF285-128=157m, AR consumed399m https://www.sec.gov/Archives/edgar/data/1306830/000130683026000117/ce-20260630.htm . FY700–800mFCF forecast requires543–643mH2,3.46–4.10xH1.4.2025risk factors show sole-sourceCO/steam/ethylene and50%-ownedFairway methanol concentration https://www.sec.gov/Archives/edgar/data/1306830/000130683026000031/ce-20251231.htm . Conclusion: real bottleneck watch, no proven incremental shareowner cash yet. Binding constraint is delivered CE margin/collections, not a shortage headline. Counterexample: CE's own2024 supplier outages made integration a liability. Prior: moderate evidence of renewed rent; a new issuer volume/netback and cash bridge would materially increase confidence; letters alone do not. At45.41/FY6 EPS apparent7.57x is forward adjusted, with debt and8%tax assumption; not standalone cheapness or a justified target. Laxmi's Junequarter11.8%EBITDA margin contradicts blanket victim classification but precedesJuly force majeure. PendingNutrinova152m sale is financing/deleveraging not recurringFCF.

Premises:1 primary issuer https://www.ishares.com/us/products/239637/ishares-msci-emerging-markets-etf readSep20, Sep17 exposures Taiwan28.10/Korea20.60/China19.94=68.64%; IT42.24%;PE19.40 PB2.69.2 primary issuer https://www.ssga.com/us/en/intermediary/etfs/state-street-energy-select-sector-spdr-etf-xle Sep17 Exxon20.03/Chevron15.19=35.22%,21holdings, forwardPE12.46 trailing indexPE17.82; oil/gas90.89%.3 recurring ETF fees .72%/.08% annual, on67.37/64.63 about.485064/.051704 dollars annually, or.121266/.012926 over3months assuming constant value, already accrued in NAV (do not subtract twice). Conclusion geographical breadth and lower forwardmultiple are not proof of independent cashflow or cheapness; earnings estimates can fall. Hold one share each under fixed signal; no fundamental override. Who benefits: underlying profitable firms from investment/energy demand, managers collect fees regardless of direction. Strong counterexample: Asia earnings or dollar currency shock and energy demand collapse can harm both. No new issuer operating earnings surprise established; this is current structure, not catalyst research. Source close EEM67.03 corroborates SIP; XLE issuerSep17close cannot validate Sep18close. Independent distribution completeness still unknown.

Premises:1 EEM issuer Sep17 IT42.24%, Taiwan/Korea/China68.64%;2 IWM issuer Sep17 PE18.31 vs EEM19.40;3 QQQ issuer calls fund nondiversified and its dynamic holdings failed. Sources https://www.ishares.com/us/products/239637/ishares-msci-emerging-markets-etf ; https://www.ishares.com/us/products/239710/ishares-russell-2000-etf ; https://www.invesco.com/qqq-etf/en/about.html . EEM93.33 implies39.42USD IT,64.06USD in three domiciles. These are exposure measures, not independent cashflow valuations. Counterexample to cheapness inference: ETF PE conventions/populations may differ and omit loss-making earnings; a lower multiple does not set a defended price target. EEM issuer Sep18close67.03 agrees feed; NAV67.28 differs legitimately from exchange close, not proof of arbitrage. Sponsors benefit from inflows; do not borrow marketing diversification assurances. Fixed momentum/P90 targets govern, no value override or single-name substitution. Missing QQQ weights recorded as unknown.

Premises:1) Read primary issuer XLK/XLE/XLV pages Sep20 02UTC; snapshots remain Sep17, not new earnings.2) XLK issuer benchmark describes11 sectors collectively covering S&P500; this is broad sector coverage, not every US listing or global equity. Source https://www.ssga.com/us/en/individual/etfs/state-street-technology-select-sector-spdr-etf-xlk ; https://www.ssga.com/us/en/individual/etfs/state-street-energy-select-sector-spdr-etf-xle ; https://www.ssga.com/us/en/individual/etfs/state-street-health-care-select-sector-spdr-etf-xlv . XLK gross annual expense0.08%, quarterly distributions. Expense86.66*.0008=.069328/year, approximately.017332/quarter, embedded NAV not double-counted execution cost. Issuer warns tracking error and stressed secondary-market discounts. Inference: underlying shock -> NAV decline -> discount/illiquidity can worsen realizable fractional RTH exit. Counterexample orderly markets allow tight tracking; no actual current discount shock measured. Issuer benefits from assets/inflows; descriptions are primary product structure, not independent return forecasts. Preserve fixed ranks/targets; single-name/global/crypto expansion rejected as outside mandate. Prior concentration study3534 retained, no repeat unchanged simulation.

Premises: observations29827/29828 recheck primary historical results, not newweekendearnings. SFIX shows sequential client recovery and liquidity withoutdebt; these undermine a distress put. Lower margins and buybacks exceedingquarterFCF keep execution risk relevant. LW cash generation improved substantially as capex fell, while international profitability weakened. Neither adjustedearnings decline nor lowshareprice alone establishes futuretail direction. Counterexamples: stabilization could drive gains; renewedpricecompetition could overwhelm savings. Validity: conditionalcash-to-equitymechanism is coherent. Soundness: futurecash and marketexpectations remain unmeasured. No position or exit reset; both current tickets fail the independentpremium/payoffgate. Sources https://investors.stitchfix.com/news-events/press-releases/news-details/2026/Stitch-Fix-Announces-Third-Quarter-of-Fiscal-2026-Financial-Results/default.aspx ; https://news.lambweston.com/news-releases/news-release-details/lamb-weston-announces-q4-and-full-year-fiscal-2026-results .